IgA Nephropathy (IgAN) Clinical Trial Pipeline Analysis: 20+ Key Companies Advancing the Future of IgAN Therapeutics | DelveInsight

DelveInsight's IgA Nephropathy (IgAN) Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline IgA Nephropathy therapies in various stages of clinical development. Major pharmaceutical and biotech companies are actively working to advance the IgAN pipeline landscape and improve future treatment opportunities for patients suffering from this progressive kidney disorder.

Key takeaways from the IgA Nephropathy Clinical Trial Landscape Report
• DelveInsight's IgA Nephropathy pipeline report depicts a growing and competitive landscape with 20+ active companies developing therapies for IgAN treatment.
• Key IgAN companies such as Vertex Pharmaceuticals, Novartis AG, Biohaven Pharmaceuticals, Rona Therapeutics, Infinimmune, Keymed Biosciences, and Nanjing Chia-tai Tianqing Pharmaceutical are actively advancing their pipeline candidates.
• Promising IgAN pipeline therapies in various stages of development include Povetacicept, Zigakibart, NTQ5082, BHV-1400, CM313, IFX 301, and others.

Request a sample and discover the recent advances in IgA Nephropathy treatment drugs:
https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is IgA Nephropathy (IgAN)?
IgA Nephropathy (IgAN), also known as Berger's disease, is the most common primary glomerular disease that may progress to end-stage renal disease (ESRD). The disease occurs when IgA deposits accumulate in the kidneys, leading to inflammation and progressive kidney tissue damage. IgAN is considered an autoimmune disease associated with galactose-deficient IgA1 and circulating anti-glycan antibodies.

Patients with IgAN may present with symptoms including hematuria, proteinuria, hypertension, and declining kidney function. Disease progression can eventually lead to ESRD in a significant proportion of patients over time. Diagnosis generally relies on renal biopsy, histopathological evaluation, and immunofluorescence microscopy. Current treatment strategies include renin-angiotensin system inhibitors (RASIs), corticosteroids, and supportive care aimed at reducing proteinuria and preserving renal function.

Emerging IgA Nephropathy Drug Profiles

Povetacicept: Vertex Pharmaceuticals
Povetacicept is a dual inhibitor of BAFF and APRIL cytokines that regulate B-cell activation and survival. The therapy is designed to inhibit autoimmune mechanisms involved in IgAN pathogenesis and has demonstrated improved potency and pharmacokinetic properties in preclinical studies. Povetacicept is currently being evaluated in Phase III clinical development for IgA Nephropathy.

In March 2026, Vertex Pharmaceuticals announced positive interim Phase III RAINIER trial results, where povetacicept achieved a statistically significant reduction in proteinuria and favorable safety outcomes in IgAN patients.

Zigakibart: Novartis AG
Zigakibart is a monoclonal antibody targeting pathways associated with IgA nephropathy progression and is currently under Phase III clinical development. The therapy is administered subcutaneously and is being evaluated as a targeted immunological treatment approach for IgAN patients.

Learn more about the novel and emerging IgA Nephropathy pipeline therapies:
https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Recent Developments in the IgA Nephropathy Clinical Trial Landscape
• In March 2026, Vertex Pharmaceuticals announced positive data from the ongoing Phase III RAINIER trial of povetacicept in IgA nephropathy patients.
• In November 2025, the US FDA granted accelerated approval to Voyxact (sibeprenlimab-szsi) injection to reduce proteinuria in adults with primary IgA nephropathy at risk of disease progression.
• In July 2025, Purespring Therapeutics announced FDA clearance of its IND application for PS-002, enabling initiation of a Phase I/II clinical trial in primary IgA nephropathy patients.
• In September 2025, Vertex Pharmaceuticals received Breakthrough Therapy Designation (BTD) from the FDA for povetacicept in IgAN.
• In January 2025, Zai Lab and Vertex Pharmaceuticals entered into an exclusive collaboration and license agreement for development and commercialization of povetacicept in mainland China, Hong Kong SAR, Macau SAR, Taiwan region, and Singapore.
• In June 2025, Ono Pharmaceutical and Vertex Pharmaceuticals announced a strategic collaboration agreement for povetacicept commercialization in Japan and South Korea.

Scope of the IgA Nephropathy Pipeline Report
• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Preclinical, Phase I, Phase II, Phase III
• Therapeutic Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, and others
• Therapeutic Assessment By Molecule Type: Monoclonal antibodies, Recombinant fusion proteins, Small molecules, RNA interference therapies, and others
• Key IgA Nephropathy Companies: Vertex Pharmaceuticals, Novartis AG, Biohaven Pharmaceuticals, Keymed Biosciences, Infinimmune, and others
• Key IgA Nephropathy Pipeline Therapies: Povetacicept, Zigakibart, NTQ5082, BHV-1400, CM313, and others

Dive deep into rich insights for new drugs for IgA Nephropathy treatment:
https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents
1. IgA Nephropathy Pipeline Report Introduction
2. IgA Nephropathy Executive Summary
3. IgA Nephropathy Overview
4. Pipeline Therapeutics
5. Late-stage Products (Phase III)
6. Mid-stage Products (Phase II)
7. Early-stage Products (Phase I/II and Phase I)
8. Preclinical Stage Products
9. Therapeutic Assessment
10. Inactive Products
11. Collaborations Assessment (Licensing/Partnering/Funding)
12. IgA Nephropathy Unmet Needs
13. Market Drivers and Barriers
14. Appendix
15. About DelveInsight

For further information on the IgA Nephropathy pipeline therapeutics, reach out:
https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve performance through market intelligence, competitive benchmarking, pipeline analysis, and consulting services. DelveInsight also offers access to healthcare and pharma market research reports through its proprietary platform PharmDelve.

This release was published on openPR.